TaiGen Biopharmaceuticals Holdings Limited, through its subsidiary, TaiGen Biotechnology Co., Ltd., engages in the development of novel therapeutics for infectious diseases, cancer, and diabetes-related complications in Taiwan and internationally. Its product portfolio includes Taigexyn (Nemonoxacin), a novel non-fluorinated quinolone antibacterial drug for the treatment of bacterial infections. The company’s development projects comprise Nemonoxacin for treating community-acquired pneumonia and diabetic foot infection; Burixafor (TG-0054), a CXCR4 chemokine receptor antagonist for stem cell transplantation and hematological cancer chemosensitization, as well as for treating myocardial infarction; and Furaprevir (TG-2349), a novel inhibitor of Hepatitis C virus NS3/4A protease. TaiGen Biopharmaceuticals Holdings Limited was founded in 2001 and is based in Taipei, Taiwan.
taigen biopharmaceuticals (4157:Taiwan)
138 Shin Ming Road
Phone: 886 2 8177 7072
Fax: 886 2 2796 3606www.taigenbiotech.com.tw
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content.
|No competitor information is available for 4157.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact TAIGEN BIOPHARMACEUTICALS, please visit www.taigenbiotech.com.tw. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.